首页> 外文期刊>Clinical Science >Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study
【24h】

Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study

机译:在正常至中度高胆固醇血症的非肥胖受试者中,植物甾烷醇酯的消耗不会增加血清前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型的浓度。血流干预研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) cholesterol (LDL-C) metabolism by targeting LDL receptors for degradation. Statins increase serum PCSK9 concentration limiting the potential of statins to reduce LDL-C, whereas ezetimibe, inhibitor of cholesterol absorption, has ambiguous effects on circulating PCSK9 levels. Plant stanols also reduce cholesterol absorption, but their effect on serum PCSK9 concentration is not known. Therefore, we performed a controlled, randomized, double-blind study, in which 92 normo-to moderately hypercholesterolaemic subjects (35 males and 57 females) consumed vegetable-oil spread 20 g/day enriched (plant stanol group, n = 46) or not (control group, n = 46) with plant stanols 3 g/day as ester for 6 months. Fasting blood samples were drawn at baseline and at the end of the study. Serum PCSK9 concentration was analysed with Quantikine Elisa Immunoassay, serum and lipoprotein lipids enzymatically and serum non-cholesterol sterols with GLC. At baseline, PCSK9 concentration varied from 91 to 716 ng/ml with a mean value of 278 +/- 11 (S.E.M.) ng/ml with no gender difference. It correlated with serum and LDL-C, serum triglycerides, age, body mass index (BMI) and plasma glucose concentration, but not with variables of cholesterol metabolism when adjusted to serum cholesterol. Plant stanols reduced LDL-C by 10% from controls (P < 0.05), but PCSK9 levels were unchanged and did not differ between the groups. In conclusion, the present study demonstrated for the first time that inhibition of cholesterol absorption with plant stanol esters did not affect serum PCSK9 concentration. Thus, plant stanol esters provide an efficient dietary means to lower LDL-C without interfering with the PCSK9 metabolism and in this regard the LDL receptor-mediated cellular cholesterol uptake and removal.
机译:前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9)通过靶向降解LDL受体来调节低密度脂蛋白(LDL)胆固醇(LDL-C)代谢。他汀类药物增加血清PCSK9浓度,限制了他汀类药物降低LDL-C的潜力,而胆固醇吸收抑制剂依泽替米贝对循环PCSK9水平有模糊影响。植物甾烷醇也可降低胆固醇的吸收,但它们对血清PCSK9浓度的影响尚不清楚。因此,我们进行了一项对照,随机,双盲研究,其中92名正常至中度高胆固醇血症的受试者(男性35例,女性57例)消耗了每天20 g富含植物油的植物油(植物甾烷醇组,n = 46)或否(对照组,n = 46),使用植物甾烷醇3 g /天作为酯,持续6个月。在基线和研究结束时抽取空腹血液样品。血清PCSK9浓度通过Quantikine Elisa免疫分析,酶促血清和脂蛋白脂质以及血清非胆固醇甾醇进行GLC分析。在基线时,PCSK9的浓度从91到716 ng / ml不等,平均值为278 +/- 11(S.E.M.)ng / ml,无性别差异。它与血清和LDL-C,血清甘油三酸酯,年龄,体重指数(BMI)和血浆葡萄糖浓度相关,但与血清胆固醇调整后的胆固醇代谢无关。植物甾烷醇使LDL-C与对照组相比降低了10%(P <0.05),但PCSK9水平没有变化,两组之间也没有差异。总之,本研究首次证明了用植物甾烷醇酯抑制胆固醇吸收不会影响血清PCSK9的浓度。因此,植物甾烷醇酯提供了降低LDL-C的有效饮食手段,而不会干扰PCSK9的代谢,在这方面,LDL受体介导的细胞胆固醇的摄取和去除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号